Diagnostic Precision

A SeraCare blog focused on precision medicine and advanced clinical diagnostics

Choose your Article Focus | NGS | Molecular & Serology

So Many Posters, So Little Time

Catagory: ctDNA, AACR, RNA fusion, TMB

Posted by Sam Blier on Jun 6, 2019 10:32:00 AM
Cancer research is purposely methodical and measured. So – somewhat paradoxically – it can be difficult to keep up with the steady stream of discoveries in the literature and presented at conferences like AACR. As a developer and manufacturer of platform-agnostic NGS reference standards, we’re in a unique position to collaborate with cancer genomics assay developers, laboratories, pharmaceutical companies, and other organizations invested in more precise and robust cancer tests.
Read More

Newly Published Multi-Laboratory Study Provides Utility and Validation of the Use of ctDNA Reference Standards

Catagory: ctDNA, cfDNA

Posted by Russell Garlick on May 30, 2019 3:32:00 PM
I am pleased to share findings from a newly published peer-reviewed study with foundational circulating tumor DNA (ctDNA) pre-analytical and analytical testing in multiple technologies and assay chemistries. The study, “Multi-laboratory Assessment of a New Reference Material for Quality Assurance of Cell-Free Tumor DNA Measurements,” was just published in The Journal of Molecular Diagnostics (He, Stein et al. 2019).
Read More

Customer Data: Use of Seraseq ctDNA Reference Samples to Validate Detection of Low Frequency Variants in a cfDNA-based NGS Lung Cancer Panel

Catagory: ctDNA, SeraSeq, AMP, cfDNA, Lung Cancer

Posted by Omo Clement, Ph.D. on Feb 14, 2019 2:10:00 PM
At the recently-concluded 2018 AMP Meeting, researchers at the New York Presbyterian Hospital (NYPH) and Weill Cornell Medical Center (WCMC) presented a poster1 on the validation of an Oncomine™ cell-free DNA Lung Assay using ctDNA NGS standards developed by SeraCare (Seraseq® ctDNA v2 Reference Materials),2
Read More

Keys to Better Liquid Biopsy Assay Sensitivity – AMP Corporate Workshop Video

Catagory: NGS, ctDNA, AMP, liquid biopsy

Posted by Sam Blier on Jan 24, 2019 10:30:00 AM
“So as everyone here is aware, I’m sure, detection of circulating tumor DNA is challenging. There’s very little of it, to start with.” Hardly a revolutionary statement by Tony Godfrey, PhD, (Associate Chair, Surgical Research and Associate Professor of Surgery, Boston University School of Medicine) but an important acknowledgement from a leading expert of the difficulty faced by laboratorians
Read More

Tips for Better EGFR Mutation Testing

Catagory: ctDNA, SeraSeq, EGFR

Posted by Catherine Huang on Jan 10, 2019 11:30:00 AM
Tips for Better EGFR Mutation Testing Molecular testing of genomic alterations in the EGFR gene is critical to personalized treatment decisions for patients with advanced non-small cell lung cancer (NSCLC). However, the testing landscape is complex. Some mutations confer sensitivity, and others confer resistance to anti-EGFR targeted therapies.
Read More

Two Must-See Liquid Biopsy Poster Videos From AMP 2018

Catagory: ctDNA, SeraSeq, AMP, liquid biopsy, cfDNA

Posted by Sam Blier on Dec 7, 2018 2:19:00 PM
  Of the many fantastic posters presented at AMP’s Annual Meeting in San Antonio, two concerning NGS-based liquid biopsy assays stood out. Both presenters described how their organizations are working to reliably detect pathogenic variants at extremely low allele frequencies – efforts critical to the clinical adoption of NGS-based liquid biopsy assays.
Read More

How A New Generation of ctDNA Reference Standards Are Enabling the Promise of Precision Medicine

Catagory: cancer, NGS, ctDNA, SeraSeq, liquid biopsy

Posted by Omo Clement, Ph.D. on Jun 14, 2018 10:00:00 AM
An important goal in cancer disease management is early detection. When detected early, disease progression can be significantly mitigated with a plethora of options (targeted therapy, chemotherapy, surgery, etc.) available to medical practitioners, to afford progression free survival and a higher quality of life. A great promise of liquid biopsies is the possibility of early detection of cancer long before clear evidence of lesions and tumor growth observable by imaging or other techniques.1 As proxy for solid tissue biopsies, plasma-based liquid biopsy application is rapidly gaining traction in cancer disease diagnosis, progression, monitoring, and in predicting resistance to treatment options.2
Read More

Sensitive ctDNA Assays are Required for Minimal Residual Cancer Detection

Catagory: ctDNA, SeraSeq

Posted by Russell Garlick on May 29, 2018 3:10:00 PM
The 11th International Symposium on Minimal Residual Cancer was held this month and much of the conference was devoted to new minimally invasive methods for circulating tumor cell enrichment and or the analysis of circulating tumor DNA. Today’s clinical needs are to measure disease burden, track mutations over time, or to detect early resistance and all of these applications require extremely sensitive, robust assays.
Read More

An Efficient and Ultrasensitive NGS Solution for Profiling ctDNA [Poster Talk Video]

Catagory: NGS, ctDNA, liquid biopsy

Posted by Trevor Brown on Mar 5, 2018 8:28:14 AM
SeraCare Customer Poster Talk Video with Data Presented by Asuragen Next-generation sequencing (NGS) of liquid biopsies offers a minimally invasive alternative to solid tissue biopsies and a more holistic profile of intra- and inter-tumoral heterogeneity for therapy selection and disease monitoring.  Watch the video and download this free poster to learn:
Read More

Accelerating Liquid Biopsy Assay Development

Catagory: ctDNA, liquid biopsy, Assay Development, reference materials

Posted by Sam Blier on Sep 8, 2017 11:15:00 AM
At the 2017 Next Generation Dx Summit in Washington, DC, our CSO, Russell Garlick, PhD, presented a workshop on accelerating liquid biopsy assay development. He has worked closely with a variety of groups in the liquid biopsy space that are developing and validating circulating tumor DNA (ctDNA) assays. He highlighted some common challenges facing the field, and explained how SeraCare has been using these collaborations to develop QC tools specifically for ensuring the robustness of these cutting-edge tests.
Read More